Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET - PubMed (original) (raw)
. 1997 Feb 13;385(6617):634-6.
doi: 10.1038/385634a0.
T Suhara, K Suzuki, K Kobayashi, O Inoue, O Terasaki, Y Someya, T Sassa, Y Sudo, E Matsushima, M Iyo, Y Tateno, M Toru
Affiliations
- PMID: 9024661
- DOI: 10.1038/385634a0
Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET
Y Okubo et al. Nature. 1997.
Abstract
Schizophrenia is believed to involve altered activation of dopamine receptors, and support for this hypothesis comes from the antipsychotic effect of antagonists of the dopamine D2 receptor (D2R). D2R is expressed most highly in the striatum, but most of the recent positron emission tomography (PET) studies have failed to show any change in D2R densities in the striatum of schizophrenics, raising the possibility that other receptors may also be involved. In particular, the dopamine D1 receptor (D1R), which is highly expressed in the prefrontal cortex, has been implicated in the control of working memory, and working memory dysfunction is a prominent feature of schizophrenia. We have therefore used PET to examine the distribution of D1R and D2R in brains of drug-naive or drug-free schizophrenic patients. Although no differences were observed in the striatum relative to control subjects, binding of radioligand to D1R was reduced in the prefrontal cortex of schizophrenics. This reduction was related to the severity of the negative symptoms (for instance, emotional withdrawal) and to poor performance in the Wisconsin Card Sorting Test. We propose that dysfunction of D1R signalling in the prefrontal cortex may contribute to the negative symptoms and cognitive deficits seen in schizophrenia.
Comment in
- Schizophrenia. An emerging pathophysiology.
Nestler EJ. Nestler EJ. Nature. 1997 Feb 13;385(6617):578-9. doi: 10.1038/385578a0. Nature. 1997. PMID: 9024651 No abstract available.
Similar articles
- [Distribution and function of dopamine D1, D2 receptor].
Suhara T, Miyoshi M. Suhara T, et al. Rinsho Shinkeigaku. 2007 Nov;47(11):826-8. Rinsho Shinkeigaku. 2007. PMID: 18210808 Review. Japanese. - Striatal dopamine D1 and D2 receptor balance in twins at increased genetic risk for schizophrenia.
Hirvonen J, van Erp TG, Huttunen J, Någren K, Huttunen M, Aalto S, Lönnqvist J, Kaprio J, Cannon TD, Hietala J. Hirvonen J, et al. Psychiatry Res. 2006 Jan 30;146(1):13-20. doi: 10.1016/j.pscychresns.2005.10.004. Epub 2005 Dec 19. Psychiatry Res. 2006. PMID: 16361088 - Ultrastructural analysis of prefrontal cortical inputs to the rat amygdala: spatial relationships to presumed dopamine axons and D1 and D2 receptors.
Pinto A, Sesack SR. Pinto A, et al. Brain Struct Funct. 2008 Sep;213(1-2):159-75. doi: 10.1007/s00429-008-0180-6. Epub 2008 Mar 14. Brain Struct Funct. 2008. PMID: 18340460 - [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L. Mechri A, et al. Encephale. 2001 Jan-Feb;27(1):53-9. Encephale. 2001. PMID: 11294039 Review. French. - Changes in cortical dopamine D1 receptor binding associated with cognitive training.
McNab F, Varrone A, Farde L, Jucaite A, Bystritsky P, Forssberg H, Klingberg T. McNab F, et al. Science. 2009 Feb 6;323(5915):800-2. doi: 10.1126/science.1166102. Science. 2009. PMID: 19197069
Cited by
- Dopamine D1 receptor in medial prefrontal cortex mediates the effects of TAAR1 activation on chronic stress-induced cognitive and social deficits.
Sun M, Zhang Y, Zhang XQ, Zhang Y, Wang XD, Li JT, Si TM, Su YA. Sun M, et al. Neuropsychopharmacology. 2024 Jul;49(8):1341-1351. doi: 10.1038/s41386-024-01866-7. Epub 2024 Apr 24. Neuropsychopharmacology. 2024. PMID: 38658737 - Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia.
Alvarez-Herrera S, Rosel Vales M, Pérez-Sánchez G, Becerril-Villanueva E, Flores-Medina Y, Maldonado-García JL, Saracco-Alvarez R, Escamilla R, Pavón L. Alvarez-Herrera S, et al. Pharmaceuticals (Basel). 2024 Jan 28;17(2):167. doi: 10.3390/ph17020167. Pharmaceuticals (Basel). 2024. PMID: 38399382 Free PMC article. - Prefrontal cortical dopamine deficit may cause impaired glucose metabolism in schizophrenia.
Wu Q, Long Y, Peng X, Song C, Xiao J, Wang X, Liu F, Xie P, Yang J, Shi Z, Hu Z, McCaig C, St Clair D, Lang B, Wu R. Wu Q, et al. Transl Psychiatry. 2024 Feb 6;14(1):79. doi: 10.1038/s41398-024-02800-7. Transl Psychiatry. 2024. PMID: 38320995 Free PMC article. - Analysis of Acute and Chronic Methamphetamine Treatment in Mice on Gdnf System Expression Reveals a Potential Mechanism of Schizophrenia Susceptibility.
Casserly L, Garton DR, Montaño-Rodriguez A, Andressoo JO. Casserly L, et al. Biomolecules. 2023 Sep 21;13(9):1428. doi: 10.3390/biom13091428. Biomolecules. 2023. PMID: 37759827 Free PMC article. - Lipid-correlated alterations in the transcriptome are enriched in several specific pathways in the postmortem prefrontal cortex of Japanese patients with schizophrenia.
Arihisa W, Kondo T, Yamaguchi K, Matsumoto J, Nakanishi H, Kunii Y, Akatsu H, Hino M, Hashizume Y, Sato S, Sato S, Niwa SI, Yabe H, Sasaki T, Shigenobu S, Setou M. Arihisa W, et al. Neuropsychopharmacol Rep. 2023 Sep;43(3):403-413. doi: 10.1002/npr2.12368. Epub 2023 Jul 27. Neuropsychopharmacol Rep. 2023. PMID: 37498306 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical